Table 1 SARS-CoV-2 cohorts used for epitope motif discovery.
SARS-CoV-2 cohorts | Â | Â | Training set | Test set | COVID-19 test | ||
|---|---|---|---|---|---|---|---|
# of donors | # of samples | # of donors | # of samples | ||||
Cohort I | Yale | Inpatient | 91 | 153 | 98 | 177 | NAT and/or serology |
| Â | Healthcare Workers | 4 | 4 | 6 | 9 | NAT and/or serology | |
| Â | Outpatient | 4 | 4 | 5 | 5 | Serology or symptoms | |
Cohort II | LabCorp | Inpatient | Â | Â | 188 | 235 | NAT |
Outpatient | Â | Â | 10 | 10 | Serology | ||
Cohort III | SBCH | In and outpatient | Â | Â | 73 | 82 | NAT, Serology |
Cohort IV | BioIVT | In and outpatient | Â | Â | 21 | 21 | Serology (20), NAT (1) |
Cohort V | BCA | Asymptomatic/mild | Â | Â | 79 | 79 | Serology/SERA |
| Â | Total | Â | 99 | 161 | 480 | 618 | Â |
| Â | Pre-pandemic Controls | IgG | 497 | 497 | 1500 | 1500 | Â |
| Â | IgM | 430 | 430 | 1498 | 1498 | Â | |
